Actually you are wrong JButler. If you research this subject, you will find that many institutions have charters that bar them from buying stocks whose share price is below $5. In some cases, it might be for all the funds an institution has, and in other cases select finds might be exempt. In addition, there are major retirement funds, etc that have these type of restrictions.
So it is very possible many institutions with this type of restriction, will based upon their due diligence, start accumulating a position in MNKD. I am not saying they will, I am simply saying that is a possibility as pointed out in the original comment by Cowboy... No rumor is needed regarding MNKD's stock. Careful research of MNKD, in the opinion of other professional analsyt and hedge funds indicates they believe MNKD's stock is an excellent investment at this point in time based upon the risk versus reward potential.
So please do not go spreading rumors JButler, and stating things that simply are not true. One thing that is obvious, commenters on this board are sharp enough to spot when commenters such as yourself post something that is false.
Check out PCYC. None of their drugs have been approved yet, but it has over 70% institutional ownership due to their breakthrough Ibrutinib cancer drug which is on the FDA fasttrack. Rocketed from less than $10 to $80-$90s in 2 years time. Current market cap 6.1B.